# Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

> **NCT04747912** · PHASE2 · SUSPENDED · sponsor: **University of Chicago** · enrollment: 25 (estimated)

## Conditions studied

- Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
- ph+ Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Inotuzumab ozogamicin
- **DRUG:** Dasatinib
- **DRUG:** Dexamethasone
- **DRUG:** Methotrexate
- **DRUG:** Vincristine
- **DRUG:** Ponatinib
- **DRUG:** Methotrexate for Injection
- **PROCEDURE:** Allogenic Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT04747912
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2021-03-02
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 25 (ESTIMATED)
- **Why stopped:** Enrollment goal met; pending amendment to expand study
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04747912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04747912, "Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04747912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*